News

Viktor Adalsteinsson

KI alum Viktor Adalsteinsson develops liquid biopsies to detect cancer

Slice of MIT

March 6, 2024

Cancer patients who undergo surgery are often left with a frightening question: Did the surgeons get all the cancerous cells? No one wants a recurrence of disease, but additional treatments such as radiation or chemotherapy have significant side effects. That’s why Viktor Adalsteinsson PhD ’15 has been developing tools to support better-informed treatment decisions: so-called “liquid biopsies” that can detect the presence of cancer from a simple blood test.

Filter by

Filter by Title/Description

Filter by Topic

Filter by Year

Showing 531–536 of 536 stories

Staggered Drug Delivery Shows Promise in Treating Aggressive Breast Cancer

MIT News

May 11, 2012

KI member Michael Yaffe and his laboratory team report finding, in the May 11 issue of Cell, that staggering the doses of two common cancer drugs dramatically boosts their ability to kill a particularly malignant type of breast cancer cells. Yaffe has been studying the complex cell signaling pathways of cancer cells and the ability of dysfunctional pathways to promote uncontrolled cell growth. He is now working with researchers at Dana Farber Cancer Institute to plan clinical trials of the novel approach.

Collaboration Key in Unique Attack on Cancer

MIT News

March 6, 2012

The Bridge Project collaboration between the Koch Institute at MIT and Dana Farber/Harvard Cancer Center (DF/HCC) awarded funding to four interdisciplinary teams on March 6, 2012. The teams will work together on two of the most lethal forms of cancer—pancreatic and glioblastoma, a type of brain cancer.  The unprecedented clinical research effort awards teams made up of biologists, bioengineers and clinical researchers from both cancer centers. It is the most extensive collaboration of its kind between Boston's two National Cancer Institute (NCI)-designated cancer centers. 

National Medal of Science Awarded to Rudolf Jaenisch

MIT News

September 27, 2011

Koch Institute member Rudolf Jaenisch has been recognized for his work that has led to major advances in our understanding of mammalian cloning and embryonic stem cells.

KI Director to be Named to National Cancer Advisory Board

The White House

September 21, 2011

In the White House announcement of his appointment, Koch Institute Director Tyler Jacks was recognized by the President for his depth of experience and tremendous dedication to cancer research.

Koch Institute and OMJP launch TRANSCEND

MIT News

June 28, 2010

KI announced a major strategic partnership with Ortho-McNeil-Janssen Pharmaceuticals, Inc., and its affiliates, called TRANSCEND, whereby the parties will begin to collaborate in multiple areas of oncology research and technology development.

David H. Koch Gives $100 Million to MIT for Cancer Research

MIT News

October 9, 2007

MIT has announced a $100 million gift from Koch Industries executive and MIT alumnus David H. Koch that will usher in new paradigms in highly integrative cancer research. The gift will bring together MIT scientists and engineers under one roof to develop new and powerful ways to detect, diagnose, treat, and manage this often deadly disease.